JPMorgan Initiates ResMed (RMD) With “Overweight” Rating and A$37.6 PT [Yahoo! Finance]
ResMed Inc. (RMD)
Last resmed inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.resmed.com/investor-relations/default.aspx
Company Research
Source: Yahoo! Finance
JPMorgan Initiates ResMed (RMD) With “Overweight” Rating and A$37.6 PT On April 15, 2026, JPMorgan initiated coverage of ResMed Inc. (NYSE:RMD) with an “Overweight” rating and an A$37.60 price target, stating that the company remains well-positioned even as investor attention increasingly shifts toward GLP-1 therapies for sleep apnea. Additionally, the firm added that although GLP-1 treatments have demonstrated meaningful clinical benefits for sleep apnea patients, they do not diminish the long-term investment case for continuous positive airway pressure therapy. At the same time, that call is significant because one of the key concerns weighing on ResMed Inc. (NYSE:RMD) has been the positive impact of Eli Lilly's Zepbound, which recently received U.S. approval for treating sleep apnea. This development could potentially hamper demand for ResMed's devices. However, ResMed Inc. (NYSE:RMD) said otherwise. During its analyst call, alongside the fiscal Q2 2026 earnings release,
Show less
Read more
Impact Snapshot
Event Time:
RMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RMD alerts
High impacting ResMed Inc. news events
Weekly update
A roundup of the hottest topics
RMD
News
- ResMed (RMD) is now covered by JPMorgan Chase & Co.. They set an "overweight" rating on the stock.MarketBeat
- ResMed (RMD) was given a new $255.00 price target by Evercore Inc. They now have an "outperform" rating on the stock.MarketBeat
- ResMed (RMD) had its price target lowered by Citigroup Inc. from $345.00 to $340.00. They now have a "buy" rating on the stock.MarketBeat
- Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026GlobeNewswire
- Is It Time To Revisit ResMed (RMD) After Recent Share Price Weakness? [Yahoo! Finance]Yahoo! Finance
RMD
Earnings
- 1/29/26 - Beat
RMD
Sec Filings
- 4/9/26 - Form 4
- 4/7/26 - Form 144
- 4/3/26 - Form 4
- RMD's page on the SEC website